IRCT20200407046981N34尚未招募未知
Comparative bioequivalence study of the Atorvastatin 80-mg/Ezetimibe 10-mg Tablet manufactured by Nikasa Pharmed Pharmaceutical Company
ikasa Pharmed Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg..
- •All volunteers must be non-smokers.They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Atorvastatin and Ezetimibe or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
招募中
不适用
In- Vivo Bioequivalence study of Atorvastatin tablets 40 mg Kharazmi Pharma with brand drugs (LIPITOR® 40 mg, Pfizer, Germany) in Iranian healthy volunteers.IRCT20200105046010N72Kharazmi Pharmaceutical Co.24
招募中
不适用
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N33Razak Pharma24
招募中
不适用
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N29Zagross Darou Pharmaceutical Company24
尚未招募
4 期
Bioequivalence Study of 80 mg Atorvastatin in healthy Thai volunteers under fasting conditioRecently,Company has manufactured a new formulation of atorvastatin tablets 80 mg for which this study has been planned to evaluate the pharmacokinetics of the new formulationTCTR20161109001Research and Development36
尚未招募
Unknown
To see how drugs Atorvastatin & Atorvastatin plus Ezetimibe have effect on lipid profile in chronic kidney disease patients : A Randomised control trialCTRI/2023/07/054891Dr Dolly Narwal